Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
4-7 July 2020

28th European Congress of Psychiatry, EPA 2020

2 July 2020

ORYZON to present at upcoming virtual international conferences

25 June 2020

ORYZON raises its share capital

19 June 2020

ORYZON enters into pioneering precision medicine collaboration with La Paz Hospital in Madrid for Phelan-McDermid Syndrome

15 June 2020

ORYZON initiates a new project to explore the efficacy of vafidemstat in the treatment of schizophrenia

12 June 2020

ORYZON presents new Phase II iadademstat efficacy data in AML at EHA-2020

11-21 June 2020

25th Congress of the European Hematology Association, EHA-2020

2 June 2020

ORYZON to present additional efficacy clinical data from ALICE Phase IIa trial with iadademstat at the 25th Congress of the European Hematology Association

1 June 2020

ORYZON publishes characterization and mechanism of action of vafidemstat, a Phase II clinical stage LSD1 inhibitor, in PLOS ONE

18 May 2020

ORYZON announces enrollment of first patient in ESCAPE: a Phase II clinical trial with vafidemstat in severely ill COVID-19 patients

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • Current page 34
  • Page 35
  • Page 36
  • Page 37
  • Page 38
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel